Quality & Compliance
Safety & Vigilance
12 october 2023
Even if physical or paper-based documents remain the most prevalent way of providing important information to users, we must consider that the Internet is increasingly being used as a vast source of information, particularly for health purposes.
With the technological advances, mobile is increasingly present in our lifestyles. It has led to us being more connected and open to these technologies, especially for all types of research and access to information. It, therefore, became clear that the pharmaceutical world could not escape from this revolution and that it had to adapt and be more future-oriented towards mobile scanning and other technologies such as QR codes (short for Quick Response Codes) and other two-dimensional (2D) or Near-Field Communication (NFC) barcodes. For example, to provide easy access to information on medical products for patients and healthcare professionals, and all this only from smartphones or other mobile devices!
Even if mobile technologies do not replace the paper version (printed leaflets, for example), the goal of using them can be various: provide easy and quicker access to data through platforms where people can retrieve information updated by the industry or the National Competent Authority (NCA) but also permits to find more easily the batch number and the expiry date for the persons impacted by visual impairment or for manufacturing, stock control, and safety aspects. This permits increased Product Information (PI) utility (video/audio). They also offer the possibility of not printing a document for an ecological purpose.
Even if mobile technologies can provide easy access to data or complementary details, the inclusion of them should require a regular review of the information published for:
Moreover, it should be noted that the PI and the additional risk minimization measures in Educational Materials must contain and provide sufficient information about the medicinal product for the patients and the healthcare professionals. The mobile technologies may include complementary information to help better clarify but should not provide additional and/or new information. Patients and professionals must be aware that even if mobile technologies can provide them with information, they should be careful about the content of the data since some information can be different from the printed version. The PI updated to the latest variation approved for the medicinal product in the system will not be implemented in the printed version simultaneously, even if printed versions must be updated as soon as possible. These discrepancies between the version available in the mobile technology and the printed one can lead to confusion and/or misunderstanding for patients and professionals. Everyone must be alerted on this aspect.
For that reason, the following sentence to inform users about the potential discrepancies with the PI provided via mobile technology should be included:
<Latest approved information [add the type of information, e.g., product information, educational material, video, etc.] on this medicine is available by scanning [the QR code][other two-dimensional (2D) bar code][Near-field Communication (NFC)] included in the <PL> <outer carton> with a smartphone/device. The same information is also available on the following URL: [URL to be included]
<and the <NCA> website >>
In the case that only the URL is mentioned in the PI (information not linked via mobile technology), the following sentence should be included:
<Latest approved information [add the type of information, e.g., product information, educational material, video, etc.] on this product is available on the following URL: [URL to be included] <and the <NCA> website >>.
This information should be inserted at the end of the PI as the last sentence, if possible. However, in the case of multilingual packaging, the recommendation is to include it at the beginning of the document.
For all the reasons presented previously, the Co-ordination group for Mutual Recognition and Decentralised procedures – human (CMDh) agreed to implement this technology in the electronic versions of the Product Information and the educational material for the patient for MRP/DCP procedures but not without some requirements and rules to follow.
For new Marketing Authorization Applications (MAA) to include mobile technologies, a declaration must be made to be evaluated during the assessment. This notification should be acceptable no later than D106 of the procedure and will be rejected if you declare this during the national phase.
This could be submitted through European Art 61(3) notification or included in a post-authorization procedure (Type IB or Type II variations with impact on PI) for authorized products.
The mobile technology feature in MRP/DCP inclusion is divided into 4 phases :
During the submission, the applicant should provide within the MAA, notification or variation dossiers (depending on the status of the medicine) in section 1.3.1 of the Module the following documentation:
Countries may propose and set minimum requirements for adopting digital e-PILs or digital platforms.
The assessment of the documentation provided through the use of mobile technology is provided by the Reference Member State (RMS) during the MRP/DCP procedure and agreed upon with Concerned Member States (CMSs) as part of the EU common phase of the assessment procedure. The RMS reviews declarations submitted as per section 5.1.
CMSs should inform if the mobile technology feature is intended for use in their Member States (MS).
The acceptability results will be based on the final English version of the platform hosting the information.
The acceptance of the mobile technology will only apply to those MS who accept the inclusion of the mobile scanning technologies.
The final content of the mobile technology in the languages required by MS will be provided at a national level for final refinement and acceptance of inclusion.
The non-statutory information, the final content of the mobile technology feature (videos and visual presentation of the platform), and the educational material will have to be finally adapted and approved by NCA after the End of Procedure (EOP) if applicable by MS.
Final documentation (e.g., mock-ups including the mobile technology feature) will be assessed by Member States at a national level, if applicable.
The mock-ups must be provided during the national phase for New MAAs, and an updated version should be provided for those countries requiring artwork for variations notifications.
After the national phase, if an applicant wants to include the mobile technology in the Product Information in another Member State(s) not stated in the declaration form submitted in the European procedure where the mobile technologies features were approved, this can be submitted nationally with the member states concerned. The MAH must provide the details of the procedure in which the dossier has been approved to facilitate national adaptation, assessment, and approval.
The applicant must consider and evaluate the following criteria depending on their case and their products to choose where they will include the mobile technology features:
ProductLife Group offers a wide range of services, particularly in the Regulatory Affairs and Regulatory Intelligence fields.
Contact us to learn more about our services and how we can help you manage interactions with Health Authorities (strategies, packaging, submission, and follow-up of dossiers) and reduce your workload.
Go to our Events to register
Go to our News to get insights